Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.67 |
| ▸ | ATM | Q13315 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | TYMS | P04818 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665992 | 0.81 | KDM4E (0.44) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL29907833 | 0.81 | MAPK1 (1.00) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL13309034 | 0.81 | MAPK1 (1.00) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL24254039 | 0.79 | MAPK1 (0.96) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL19678360 | 0.78 | KDM4E (0.41) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL19678384 | 0.77 | KDM4E (0.40) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL19665998 | 0.77 | KDM4E (0.40) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL11213974 | 0.77 | ALDH1A1 (0.61) | MAPK1ATMKDM4ETYMSCYP1A2 | |
| SCHEMBL19678377 | 0.76 | KDM4E (0.39) | MAPK1ATMKDM4ECYP1A2CYP2D6 | |
| SCHEMBL19678351 | 0.76 | KDM4E (0.42) | MAPK1ATMKDM4ETYMSCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-6916832-B2 | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-07-12 | — | — | US | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | MAPK1 4026/4885ATM 4336/4885KDM4E 4742/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | MAPK1 3346/4885ATM 3252/4885KDM4E 4653/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | MAPK1 4013/4885ATM 4325/4885KDM4E 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.